REVIEW article

Front. Pharmacol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1549694

This article is part of the Research TopicThe Role of Tumor Microenvironment in Malignant Progression and Target ValidationView all 7 articles

Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications

Provisionally accepted
Yu  ZhuYu Zhu1Xianbo  WuXianbo Wu1Li  WanLi Wan1Linyue  XuLinyue Xu1Qiuyan  ChenQiuyan Chen1Can  ZouCan Zou1Ju  HuangJu Huang2*
  • 1School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan Province, China
  • 2Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

The final, formatted version of the article will be published soon.

Gastric cancer (GC) is the fifth most common malignant tumor that imposes heavily public health burdens worldwide. Systemic therapies for gastric cancer (GC), such as chemotherapy, targeted therapy, and immunotherapy, have undergone significant advancements. Nevertheless, the extensive application of anti-cancer agents has resulted in an increasing array of challenges related to drug resistance, presenting a substantial barrier in GC treatment. Tumor-associated macrophages (TAMs) as essential immunomodulators within the tumor immune microenvironment (TIME) of GC, providing novel therapeutic targets due to their capacity for plasticity in reaction to environmental signals. They create a complex network of communication with various immune and stromal cell types, thereby contributing to the immunosuppressive nature of the TME in GC. In this review, we establish the map of the origin and polarization of macrophages in GC. During the process of carcinogenesis, macrophages undergo dynamic phenotypic transitions. Additionally, the interactions between TAMs and tumor cells significantly influence the progression of GC, affecting tumor growth, metastasis, angiogenesis, and drug resistance. Furthermore, this intricate immunomodulatory axis notably enhances resistance to immunotherapy, suggesting that targeting TAMs presents substantial therapeutic opportunities for patients with GC. Approaches such as TAM elimination, TAM repolarization, and CAR-M therapy have been validated in numerous studies. We also elaborate on the challenges faced by the development of targeting TAMs, which may provide innovative perspectives on the GC treatment.

Keywords: gastric cancer, tumor-associated macrophage, Tumor Microenvironment, tumor progression, Immunotherapy

Received: 21 Dec 2024; Accepted: 29 May 2025.

Copyright: © 2025 Zhu, Wu, Wan, Xu, Chen, Zou and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ju Huang, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.